HeartWare International names Dr. Katrin Leadley to be its new chief medical officer following the retirement of Dr. David Hathaway.
, eLux Medical
, HeartWare International Inc.
, NxStage Medical Inc.
, Revolutions Medical Corp.
, Terumo Corp.
, X2 Biosystems
, AngioDynamics Inc.
A federal judge denies NuVasive's bid to overturn a $30 million trademark infringement loss and cancels its trademark on the NeuroVision name.
NuVasive shares surge more than 10% as the medical device company raises its outlook for the rest of the year after posting 2nd-quarter sales and earnings numbers that beat estimates.
JenaValve taps ex-AtriCure chief David Drachman to be its new CEO.
, Bioject Medical Technologies Inc.
, Echo Therapeutics Inc.
, Hill-Rom Holdings Inc.
, Integrity Applications
, U.S. Veterans Affairs Dept. (VA)
, GI Dynamics
NuVasive launches the latest version of its NVM5 monitoring platform for spinal surgeries.
NuVasive Inc. (NSDQ:NUVA) said today that it's launching the next generation of its NVM5 patient monitoring platform for spine surgeries.
Here's a look at some of the top legal news stories for medical device companies this week: Justice Dept. probes St. Jude for potential False Claims, kickbacks violations; More secret human studies uncovered in Myxo ring inquiry; Medtech manufacturer fleeced Stryker, says former exec; FDA morcellator warning spurs lawsuit against J&J; NuVasive claims win in patent spat with Cadwell Labs
, Dept. of Justice (DOJ)
, Edwards Lifesciences
, Ethicon Endo-Surgery
, Ferry Machine Corp.
, Food & Drug Administration (FDA)
, Johnson & Johnson
, St. Jude Medical
, Stryker Corp.
, U.S. Senate
NuVasive says it's settled a patent infringement lawsuit over neuromonitoring technology with Cadwell Laboratories, which agreed to exit the lateral spine surgery market and might be on the hook for royalties.
NuVasive Inc. (NSDQ:NUVA) said today that Cadwell Laboratories agreed to settle a patent spat over neuromonitoring technology by exiting the lateral spine market and potentially paying 5% royalties to NuVasive for future products.